Tvardi Therapeutics to Participate at the SVB Securities Global Biopharma Conference

Houston, TX – January 31, 2023 – Tvardi Therapeutics, Inc. (“Tvardi”), a privately held, clinical-stage biopharmaceutical company focused on the development of STAT3 inhibitors, announced that the company has been invited to participate at the SVB Securities Global Biopharma Conference. The management team will hold one-on-one meetings during the conference on February 1 and 2, 2023.

About Tvardi Therapeutics
Tvardi is a privately held, clinical-stage biopharmaceutical company developing small molecule inhibitors of STAT3, a key regulatory protein positioned at the intersection of many signaling pathways integral to the survival and immune evasion of cancer cells. STAT3 also plays a central role in the pathogenesis of many inflammatory and fibrotic diseases. The company’s lead product, TTI-101, is completing a first-in-man Phase 1 trial of relapsed/refractory patients with advanced solid tumors. To date, TTI-101 monotherapy has been well-tolerated and has clinical activity across a broad range of tumors including multiple durable radiographic objective responses. The company has now initiated Phase 2 clinical programs in hepatocellular carcinoma, metastatic breast cancer, and idiopathic pulmonary fibrosis. To learn more, please visit Tvardi Therapeutics.

Tvardi Investor Relations
Sara Manning

We use cookies to ensure that we give you the best experience on our website. By using this website you agree to the Privacy Policy and  Terms of Use.